LUPIN LTD.
P&L
Quarterly Consolidated
vs Q2 FY25
LUPIN LTD. Reports Q3 FY2025 Financial Performance: Revenue and EBITDA Show Sustained Growth
12 Feb 2025 · 12 Feb 2025, 07:44 am
Summary
Pharma major Lupin Limited reported its financial performance for the quarter ending December 31, 2024. The company's revenue and EBITDA showed sustained growth, with US revenues led by building scale in new products being pivotal for growth. The India and EMEA regions also contributed significantly to the strong performance.
Key Highlights
- 1
Revenue and EBITDA showed sustained growth in Q3 FY2025
- 2
US revenues led by building scale in new products
- 3
Strong nine-month performance from India and EMEA regions
- 4
Lupin continues to maintain its leadership position in U.S. generics market and U.S. total market by prescriptions
- 5
Investment in R&D was INR 4,344 Mn (7.7% of sales) for the quarter
Management Comments
Nilesh Gupta
Our third-quarter results highlight our continued strength, with both revenue and EBITDA showing sustained growth. US revenues led by building scale in new products have been pivotal for our growth, supported by a strong nine-month performance from our India and EMEA regions. We look forward to maintaining this momentum in the ensuing quarters backed by growth in sales, commercial and operating efficiencies, and strong compliance.
Informational and educational content only. Not investment advice.